Facebook
Twitter
Telegram
Report an ErrorSutro Biopharma Balance Sheet 2011-2024 | STRO
Annual Balance Sheet Sutro Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-38.9 M | -13.6 M | -182 M | 3.92 M | -111 M | -7.39 M | -11.6 M | - | - | - | - | - | |
Long Term Debt |
- | 3.77 M | 15.7 M | 24.5 M | 8.88 M | 10 M | - | - | - | - | - | - | - |
Long Term Debt Current |
6.42 M | 4.58 M | 1.04 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 55.2 M | 118 M | 110 M | - | - | - | - | - |
Total Current Liabilities |
93.7 M | 66.5 M | 41.7 M | 29.6 M | 33 M | 36.4 M | - | - | - | - | - | - | - |
Total Liabilities |
321 M | 190 M | 88.8 M | 62.1 M | 58.6 M | 91.6 M | 150 M | 160 M | - | - | - | - | - |
Deferred Revenue |
20.7 M | 16.8 M | 5.5 M | 14.6 M | 19.5 M | 21.6 M | 10.7 M | 43.6 M | - | - | - | - | - |
Retained Earnings |
-559 M | -453 M | -333 M | -228 M | -196 M | -150 M | -115 M | -95.3 M | - | - | - | - | - |
Total Assets |
471 M | 407 M | 341 M | 394 M | 156 M | 223 M | 40.8 M | 69.3 M | - | - | - | - | - |
Cash and Cash Equivalents |
69.3 M | 47.3 M | 30.4 M | 206 M | 4.96 M | 125 M | 22 M | - | - | - | - | - | - |
Book Value |
150 M | 217 M | 253 M | 332 M | 97.8 M | 132 M | -109 M | -90.9 M | - | - | - | - | - |
Total Shareholders Equity |
150 M | 217 M | 253 M | 332 M | 97.8 M | 132 M | -109 M | -90.9 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Sutro Biopharma
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
21.4 M | 23.2 M | 24.9 M | 26.5 M | 28.1 M | 3.77 M | 6.78 M | 9.78 M | 12.8 M | 15.7 M | 18.7 M | 21.7 M | 24.7 M | 24.5 M | 24.5 M | 24.5 M | 24.5 M | 8.88 M | 8.88 M | 8.88 M | 8.88 M | 10 M | 10 M | 10 M | 10 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
305 M | 321 M | 319 M | 310 M | 173 M | 190 M | 171 M | 177 M | 83.3 M | 88.8 M | 87.9 M | 52.3 M | 51.2 M | 62.1 M | 62.1 M | 62.1 M | 62.1 M | 58.6 M | 58.6 M | 58.6 M | 58.6 M | 91.6 M | 91.6 M | 91.6 M | 91.6 M | 47.3 M | 47.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
20.5 M | 20.7 M | 24 M | 18 M | 17.2 M | 16.8 M | 15.9 M | 6.49 M | 6.28 M | 5.5 M | 7.8 M | 8.13 M | 12.1 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 21.6 M | 24.2 M | 21.6 M | 21.6 M | 10.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-618 M | -559 M | -590 M | -541 M | -503 M | -453 M | -418 M | -399 M | -373 M | -333 M | -295 M | -264 M | -258 M | -228 M | -228 M | -228 M | -228 M | -196 M | -196 M | -196 M | -196 M | -150 M | -150 M | -150 M | -150 M | -115 M | -115 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
403 M | 471 M | 432 M | 465 M | 358 M | 407 M | 401 M | 386 M | 304 M | 341 M | 371 M | 360 M | 359 M | 394 M | 394 M | 394 M | 394 M | 156 M | 156 M | 156 M | 156 M | 223 M | 223 M | 223 M | 223 M | 40.8 M | 40.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
65.2 M | 69.3 M | 81.8 M | 235 M | 62.5 M | 47.3 M | 96.8 M | 79.1 M | 28.9 M | 30.4 M | 30.7 M | 56.4 M | 55.8 M | 206 M | 206 M | 206 M | 206 M | 4.96 M | 4.96 M | 4.96 M | 4.96 M | 125 M | 125 M | 125 M | 125 M | 22 M | 22 M | - | - | 11.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
98 M | 150 M | 112 M | 155 M | 185 M | 217 M | 230 M | 209 M | 220 M | 253 M | 284 M | 308 M | 307 M | 332 M | 332 M | 332 M | 332 M | 97.8 M | 97.8 M | 97.8 M | 97.8 M | 132 M | 132 M | 132 M | 132 M | -6.5 M | -6.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
98 M | 150 M | 112 M | 155 M | 185 M | 217 M | 230 M | 209 M | 220 M | 253 M | 284 M | 308 M | 307 M | 332 M | 332 M | 332 M | 332 M | 97.8 M | 97.8 M | 97.8 M | 97.8 M | 132 M | 132 M | 132 M | 132 M | -109 M | -109 M | - | - | -90.9 M | - | - | - | -93.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency